المؤلفون: Rivoltini, Licia, Camisaschi, Chiara, Fucà, Giovanni, Paolini, Biagio, Vergani, Barbara, Beretta, Valeria, Damian, Silvia, Duca, Matteo, Cresta, Sara, Magni, Michele, Leone, Biagio Eugenio, Castelli, Chiara, de Braud, Filippo, De Santis, Francesca, Di Nicola, Massimo

المساهمون: Rivoltini, L, Camisaschi, C, Fucà, G, Paolini, B, Vergani, B, Beretta, V, Damian, S, Duca, M, Cresta, S, Magni, M, Leone, B, Castelli, C, de Braud, F, De Santis, F, Di Nicola, M

مصطلحات موضوعية: triple-negative breast cancer, PD-1, LAG-3

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38336861; info:eu-repo/semantics/altIdentifier/wos/WOS:001160750400058; volume:14; issue:1; journal:SCIENTIFIC REPORTS; https://hdl.handle.net/10281/460058Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85184786154

الإتاحة: https://doi.org/10.1038/s41598-024-54041-9Test
https://hdl.handle.net/10281/460058Test

المؤلفون: Mačak Šafranko, Željka, Jakopec, Lana, Svaguša, Karla, Cvetko Krajinović, Lidija, Tomasović, Domagoj, Lukić, Ljiljana, Markotić, Alemka

المصدر: https://www.mdpi.com/2075-1729/14/5/551Test ; Life ; Volume 14 ; Issue 5 ; ISSN 2075-1729 (Online.

مصطلحات موضوعية: orthohantavirus, HFRS, PUUV, inhibitory receptors, immune regulations, TIM-3, LAG-3, PD-1, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology

وصف الملف: application/pdf

العلاقة: Sveučilište u Rijeci. Medicinski fakultet. Katedra za zarazne bolesti.; University of Rijeka. Faculty of Medicine. Department of Infectious Diseases.; https://www.unirepository.svkri.uniri.hr/islandora/object/medri:8567Test; https://urn.nsk.hr/urn:nbn:hr:184:230383Test; https://www.unirepository.svkri.uniri.hr/islandora/object/medri:8567/datastream/FILE0Test

الإتاحة: https://doi.org/10.3390/life14050551Test
https://www.unirepository.svkri.uniri.hr/islandora/object/medri:8567Test
https://urn.nsk.hr/urn:nbn:hr:184:230383Test
https://www.unirepository.svkri.uniri.hr/islandora/object/medri:8567/datastream/FILE0Test

المؤلفون: Rodriguez Guilarte, Linmar Eri Jose, Ramirez Pozo, Mario Andres, Andrade Parra, Catalina Andrea, Kalergis Parra Alexis Mikes

مصطلحات موضوعية: LAG-3, Ligand, T cell dysfunction, Viral infections, Medicina y salud, 03 Good Health and Well-being, 03 Salud y bienestar

الوقت: 610

وصف الملف: 15 páginas; application/pdf

العلاقة: https://doi.org/10.3390/v15010147Test; https://repositorio.uc.cl/handle/11534/80992Test; WOS:000926169300001

الإتاحة: https://doi.org/10.3390/v15010147Test
https://repositorio.uc.cl/handle/11534/80992Test

المؤلفون: Anastasia Sergeevna Belevich, M. I. Yarmolinskaya, Sergey Alekseevich Selkov, Dmitriy Igorevich Sokolov, Анастасия Сергеевна Белевич, М. И. Ярмолинская, Сергей Алексеевич Сельков, Дмитрий Игоревич Соколов

المساهمون: Работы выполнена в рамках ФНИ № 122041500063-2

المصدر: Medical Immunology (Russia); Online First ; Медицинская иммунология; Online First ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-0-0

مصطلحات موضوعية: контрольные точки, эндометриоз, CTLA-4, PD-1, LAG-3, Tim-3, TIGIT, 4-1BB, GITR

وصف الملف: application/pdf

العلاقة: https://www.mimmun.ru/mimmun/article/view/2923/1920Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13088Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13089Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13090Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13091Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13092Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13093Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13094Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13134Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13135Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13155Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13156Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13546Test; Abramiuk M., Bebnowska D., Hrynkiewicz R., Polak P.N.G., Kotarski J., Rolinski J.,Grywalska E. CLTA-4 Expression is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility. Cells, 2021, Vol.10, no 3. [10.3390/cells10030487] https://www.ncbi.nlm.nih.gov/pubmed/33668701Test; Abramiuk M., Frankowska K., Kulak K., Tarkowski R., Mertowska P., Mertowski S.,Grywalska E. Possible Correlation between Urocortin 1 (Ucn1) and Immune Parameters in Patients with Endometriosis. Int J Mol Sci, 2023, Vol.24, no 9. [10.3390/ijms24097787] https://www.ncbi.nlm.nih.gov/pubmed/37175494Test; Agic A., Djalali S., Wolfler M.M., Halis G., Diedrich K.,Hornung D. Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reprod Sci, 2008, Vol.15, no 9, pp. 906-11. [10.1177/1933719108318598] https://www.ncbi.nlm.nih.gov/pubmed/19050323Test; Akhtar K., Sravanthi M.V., D'Angelo J.,Sivapiragasam A. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios. J Investig Med High Impact Case Rep, 2022, Vol.10, no, pp. 23247096221121408. [10.1177/23247096221121408] https://www.ncbi.nlm.nih.gov/pubmed/36017984Test; Akinboro O., Larkins E., Pai-Scherf L.H., Mathieu L.N., Ren Y., Cheng J., Fiero M.H., Fu W., Bi Y., Kalavar S., Jafri S., Mishra-Kalyani P.S., Fourie Zirkelbach J., Li H., Zhao H., He K., Helms W.S., Chuk M.K., Wang M., Bulatao I., Herz J., Osborn B.L., Xu Y., Liu J., Gong Y., Sickafuse S., Cohen R., Donoghue M., Pazdur R., Beaver J.A.,Singh H. FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC. Clin Cancer Res, 2022, Vol.28, no 11, pp. 2221-2228. [10.1158/1078-0432.CCR-21-3844] https://www.ncbi.nlm.nih.gov/pubmed/35101885Test; Alsharedi M., Srivastava R.,Elmsherghi N. Durvalumab for the treatment of urothelial carcinoma. Drugs Today (Barc), 2017, Vol.53, no 12, pp. 647-652. [10.1358/dot.2017.53.12.2733054] https://www.ncbi.nlm.nih.gov/pubmed/29517083Test; Anglesio M.S., Papadopoulos N., Ayhan A., Nazeran T.M., Noe M., Horlings H.M., Lum A., Jones S., Senz J., Seckin T., Ho J., Wu R.C., Lac V., Ogawa H., Tessier-Cloutier B., Alhassan R., Wang A., Wang Y., Cohen J.D., Wong F., Hasanovic A., Orr N., Zhang M., Popoli M., McMahon W., Wood L.D., Mattox A., Allaire C., Segars J., Williams C., Tomasetti C., Boyd N., Kinzler K.W., Gilks C.B., Diaz L., Wang T.L., Vogelstein B., Yong P.J., Huntsman D.G.,Shih I.M. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med, 2017, Vol.376, no 19, pp. 1835-1848. [10.1056/NEJMoa1614814] https://www.ncbi.nlm.nih.gov/pubmed/28489996Test; Arabpour M., Ghods A., Shariat M., Talei A.R., Mehdipour F.,Ghaderi A. Correlation of 4-1BBL+ B Cells in Tumor Draining Lymph Nodes with Pathological Characteristics of Breast Cancer. Iran J Immunol, 2019, Vol.16, no 2, pp. 108-116. [10.22034/IJI.2019.80254] https://www.ncbi.nlm.nih.gov/pubmed/31182685Test; Atkinson V., Khattak A., Haydon A., Eastgate M., Roy A., Prithviraj P., Mueller C., Brignone C.,Triebel F. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J Immunother Cancer, 2020, Vol.8, no 2. [10.1136/jitc-2020-001681] https://www.ncbi.nlm.nih.gov/pubmed/33219094Test; Azimnasab-Sorkhabi P., Soltani-Asl M.,Kfoury Junior J.R. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Hum Cell, 2023, Vol.36, no 4, pp. 1225-1232. [10.1007/s13577-023-00893-8] https://www.ncbi.nlm.nih.gov/pubmed/36907978Test; Baptista M.Z., Sarian L.O., Derchain S.F., Pinto G.A.,Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol, 2016, Vol.47, no 1, pp. 78-84. [10.1016/j.humpath.2015.09.006] https://www.ncbi.nlm.nih.gov/pubmed/26541326Test; Bardhan K., Anagnostou T.,Boussiotis V.A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol, 2016, Vol.7, no, pp. 550. [10.3389/fimmu.2016.00550] https://www.ncbi.nlm.nih.gov/pubmed/28018338Test; Barra F., Ferro Desideri L., Leone Roberti Maggiore U., Gaetano Vellone V., Maramai M., Scala C.,Ferrero S. Endometriosis Classification and The Role of Tumor Necrosis Factor-Alpha Polymorphisms as A Therapeutic Target. Int J Fertil Steril, 2020, Vol.14, no 1, pp. 76-77. [10.22074/ijfs.2020.5876] https://www.ncbi.nlm.nih.gov/pubmed/32112641Test; Bartkowiak T.,Curran M.A. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol, 2015, Vol.5, no, pp. 117. [10.3389/fonc.2015.00117] https://www.ncbi.nlm.nih.gov/pubmed/26106583Test; Bettini M., Szymczak-Workman A.L., Forbes K., Castellaw A.H., Selby M., Pan X., Drake C.G., Korman A.J.,Vignali D.A. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol, 2011, Vol.187, no 7, pp. 3493-8. [10.4049/jimmunol.1100714] https://www.ncbi.nlm.nih.gov/pubmed/21873518Test; Borrelli G.M., Abrao M.S.,Mechsner S. Can chemokines be used as biomarkers for endometriosis? A systematic review. Hum Reprod, 2014, Vol.29, no 2, pp. 253-66. [10.1093/humrep/det401] https://www.ncbi.nlm.nih.gov/pubmed/24287816Test; Brinton L.A., Gridley G., Persson I., Baron J.,Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol, 1997, Vol.176, no 3, pp. 572-9. [10.1016/s0002-9378(97)70550-7] https://www.ncbi.nlm.nih.gov/pubmed/9077609Test; Brinton L.A., Sakoda L.C., Sherman M.E., Frederiksen K., Kjaer S.K., Graubard B.I., Olsen J.H.,Mellemkjaer L. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev, 2005, Vol.14, no 12, pp. 2929-35. [10.1158/1055-9965.EPI-05-0394] https://www.ncbi.nlm.nih.gov/pubmed/16365012Test; Brubel R., Bokor A., Pohl A., Schilli G.K., Szereday L., Bacher-Szamuel R., Rigo J., Jr.,Polgar B. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril, 2017, Vol.108, no 6, pp. 1016-1025 e2. [10.1016/j.fertnstert.2017.09.008] https://www.ncbi.nlm.nih.gov/pubmed/29202955Test; Burghaus S., Drazic P., Wolfler M., Mechsner S., Zeppernick M., Meinhold-Heerlein I., Mueller M.D., Rothmund R., Vigano P., Becker C.M., Zondervan K.T., Beckmann M.W., Fasching P.A., Berner-Gatz S., Grunewald F.S., Hund M., Kastner P., Klammer M., Laubender R.P., Wegmeyer H., Wienhues-Thelen U.H.,Renner S.P. Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. Int J Gynaecol Obstet, 2023 no. [10.1002/ijgo.15062] https://www.ncbi.nlm.nih.gov/pubmed/37635683Test; Cakir Y., Talu C.K., Trabulus D.C.,Mermut O. The immunohistochemical Galectin-3 expression in tumor and cancer-associated fibroblasts in invasive ductal carcinomas of breast and their relationship with clinicopathological parameters. Indian J Pathol Microbiol, 2023, Vol.66, no 3, pp. 456-464. [10.4103/ijpm.ijpm_284_21] https://www.ncbi.nlm.nih.gov/pubmed/37530324Test; Canales Rojas R. Update on immunotherapy for renal cancer. Medwave, 2021, Vol.21, no 5, pp. e8202. [10.5867/medwave.2021.05.8202] https://www.ncbi.nlm.nih.gov/pubmed/34214067Test; Cao Y., Zhou X., Huang X., Li Q., Gao L., Jiang L., Huang M.,Zhou J. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One, 2013, Vol.8, no 1, pp. e53834. [10.1371/journal.pone.0053834] https://www.ncbi.nlm.nih.gov/pubmed/23335978Test; Caserta D., Di Benedetto L., Bordi G., D'Ambrosio A.,Moscarini M. Levels of Galectin-3 and Stimulation Expressed Gene 2 in the peritoneal fluid of women with endometriosis: a pilot study. Gynecol Endocrinol, 2014, Vol.30, no 12, pp. 877-80. [10.3109/09513590.2014.943728] https://www.ncbi.nlm.nih.gov/pubmed/25069762Test; Chambers C.A., Kuhns M.S., Egen J.G.,Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol, 2001, Vol.19, no, pp. 565-94. [10.1146/annurev.immunol.19.1.565] https://www.ncbi.nlm.nih.gov/pubmed/11244047Test; Chattopadhyay S.,Chakraborty N.G. GITR expression on T-cell receptor-stimulated human CD8 T cell in a JNK-dependent pathway. Indian J Hum Genet, 2009, Vol.15, no 3, pp. 121-4. [10.4103/0971-6866.60188] https://www.ncbi.nlm.nih.gov/pubmed/21088717Test; Chen S., Liu Y., Zhong Z., Wei C., Liu Y.,Zhu X. Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives. Front Immunol, 2023, Vol.14, no, pp. 1134663. [10.3389/fimmu.2023.1134663] https://www.ncbi.nlm.nih.gov/pubmed/36865552Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971222/pdf/fimmu-14-1134663.pdfTest; Chen T., Wei J.L., Leng T., Gao F.,Hou S.Y. The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis. J Clin Lab Anal, 2021, Vol.35, no 9, pp. e23947. [10.1002/jcla.23947] https://www.ncbi.nlm.nih.gov/pubmed/34405450Test; Chen W.C., Cheng C.M., Liao W.T.,Chang T.C. Urinary Biomarkers for Detection of Clinical Endometriosis or Adenomyosis. Biomedicines, 2022, Vol.10, no 4. [10.3390/biomedicines10040833] https://www.ncbi.nlm.nih.gov/pubmed/35453583Test; https://mdpi-res.com/d_attachment/biomedicines/biomedicines-10-00833/article_deploy/biomedicines-10-00833.pdf?version=1648819036Test; Chen X., Du Y., Hu Q.,Huang Z. Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res Pract, 2017, Vol.213, no 3, pp. 245-249. [10.1016/j.prp.2016.12.008] https://www.ncbi.nlm.nih.gov/pubmed/28214198Test; Chen Z., Huang J., Kwak-Kim J.,Wang W. Immune checkpoint inhibitors and reproductive failures. J Reprod Immunol, 2023, Vol.156, no, pp. 103799. [10.1016/j.jri.2023.103799] https://www.ncbi.nlm.nih.gov/pubmed/36724630Test; Cheng L.S., Cheng Y.F., Liu W.T., Shen A., Zhang D., Xu T., Yin W., Cheng M., Ma X., Wang F., Zhao Q., Zeng X., Zhang Y.,Shen G. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med, 2022, Vol.20, no 1, pp. 415. [10.1186/s12967-022-03619-w] https://www.ncbi.nlm.nih.gov/pubmed/36076251Test; Chester C., Ambulkar S.,Kohrt H.E. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother, 2016, Vol.65, no 10, pp. 1243-8. [10.1007/s00262-016-1829-2] https://www.ncbi.nlm.nih.gov/pubmed/27034234Test; Chester C., Sanmamed M.F., Wang J.,Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 2018, Vol.131, no 1, pp. 49-57. [10.1182/blood-2017-06-741041] https://www.ncbi.nlm.nih.gov/pubmed/29118009Test; Choi Y.S., Kim S., Oh Y.S., Cho S.,Hoon Kim S. Elevated serum interleukin-32 levels in patients with endometriosis: A cross-sectional study. Am J Reprod Immunol, 2019, Vol.82, no 2, pp. e13149. [10.1111/aji.13149] https://www.ncbi.nlm.nih.gov/pubmed/31099938Test; Claus C., Ferrara-Koller C.,Klein C. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs, 2023, Vol.15, no 1, pp. 2167189. [10.1080/19420862.2023.2167189] https://www.ncbi.nlm.nih.gov/pubmed/36727218Test; Collins J.M.,Gulley J.L. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother, 2019, Vol.15, no 4, pp. 891-908. [10.1080/21645515.2018.1551671] https://www.ncbi.nlm.nih.gov/pubmed/30481100Test; Contardi E., Palmisano G.L., Tazzari P.L., Martelli A.M., Fala F., Fabbi M., Kato T., Lucarelli E., Donati D., Polito L., Bolognesi A., Ricci F., Salvi S., Gargaglione V., Mantero S., Alberghini M., Ferrara G.B.,Pistillo M.P. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer, 2005, Vol.117, no 4, pp. 538-50. [10.1002/ijc.21155] https://www.ncbi.nlm.nih.gov/pubmed/15912538Test; Daud A.I., Wolchok J.D., Robert C., Hwu W.J., Weber J.S., Ribas A., Hodi F.S., Joshua A.M., Kefford R., Hersey P., Joseph R., Gangadhar T.C., Dronca R., Patnaik A., Zarour H., Roach C., Toland G., Lunceford J.K., Li X.N., Emancipator K., Dolled-Filhart M., Kang S.P., Ebbinghaus S.,Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol, 2016, Vol.34, no 34, pp. 4102-4109. [10.1200/JCO.2016.67.2477] https://www.ncbi.nlm.nih.gov/pubmed/27863197Test; De Mello R.A.B., Voscaboinik R., Luciano J.V.P., Cremonese R.V., Amaral G.A., Castelo-Branco P.,Antoniou G. Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers (Basel), 2021, Vol.14, no 1. [10.3390/cancers14010122] https://www.ncbi.nlm.nih.gov/pubmed/35008287Test; Duan X., Liu J., Cui J., Ma B., Zhou Q., Yang X., Lu Z., Du Y.,Su C. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. Mol Med Rep, 2019, Vol.20, no 4, pp. 3773-3781. [10.3892/mmr.2019.10641] https://www.ncbi.nlm.nih.gov/pubmed/31485637Test; Dumic J., Dabelic S.,Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta, 2006, Vol.1760, no 4, pp. 616-35. [10.1016/j.bbagen.2005.12.020] https://www.ncbi.nlm.nih.gov/pubmed/16478649Test; Eggermont A.M.,Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer, 2011, Vol.47, no 14, pp. 2150-7. [10.1016/j.ejca.2011.06.052] https://www.ncbi.nlm.nih.gov/pubmed/21802280Test; Eurich K., De La Cruz P., Laguna A., Woodman M., McAdams J., Lips E., Ebott J., DiSilvestro J., Ribeiro J.,James N. Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer. Gynecol Oncol, 2023, Vol.174, no, pp. 200-207. [10.1016/j.ygyno.2023.05.015] https://www.ncbi.nlm.nih.gov/pubmed/37224792Test; Finkelmeier F., Waidmann O.,Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther, 2018, Vol.18, no 12, pp. 1169-1175. [10.1080/14737140.2018.1535315] https://www.ncbi.nlm.nih.gov/pubmed/30304963Test; Geng H., Zhang G.M., Xiao H., Yuan Y., Li D., Zhang H., Qiu H., He Y.F.,Feng Z.H. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer, 2006, Vol.118, no 11, pp. 2657-64. [10.1002/ijc.21795] https://www.ncbi.nlm.nih.gov/pubmed/16425224Test; Gu Q., Li J., Chen Z., Zhang J., Shen H., Miao X., Zhou Y., Xu X.,He S. Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma. Front Oncol, 2021, Vol.11, no, pp. 664032. [10.3389/fonc.2021.664032] https://www.ncbi.nlm.nih.gov/pubmed/34178648Test; Guney G., Taskin M.I., Lagana A.S., Tolu E., Aslan F., Hismiogullari A.A.,Kaya C. Neutrophil gelatinase-associated lipocalin serum level: A potential noninvasive biomarker of endometriosis? Medicine (Baltimore), 2023, Vol.102, no 41, pp. e35539. [10.1097/MD.0000000000035539] https://www.ncbi.nlm.nih.gov/pubmed/37832065Test; Guo B., Chen J.H., Zhang J.H., Fang Y., Liu X.J., Zhang J., Zhu H.Q.,Zhan L. Pattern-recognition receptors in endometriosis: A narrative review. Front Immunol, 2023, Vol.14, no, pp. 1161606. [10.3389/fimmu.2023.1161606] https://www.ncbi.nlm.nih.gov/pubmed/37033937Test; Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T., Baldwin D.T., Gray A.M., Dowd A.D., Brush A.D., Heldens A.D., Schow A.D., Goddard A.D., Wood W.I., Baker K.P., Godowski P.J.,Ashkenazi A. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol, 1999, Vol.9, no 4, pp. 215-8. [10.1016/s0960-9822(99)80093-1] https://www.ncbi.nlm.nih.gov/pubmed/10074428Test; Hafler D.A.,Kuchroo V. TIMs: central regulators of immune responses. J Exp Med, 2008, Vol.205, no 12, pp. 2699-701. [10.1084/jem.20082429] https://www.ncbi.nlm.nih.gov/pubmed/19015312Test; Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T.,Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A, 2007, Vol.104, no 9, pp. 3360-5. [10.1073/pnas.0611533104] https://www.ncbi.nlm.nih.gov/pubmed/17360651Test; He Y., Jia K., Dziadziuszko R., Zhao S., Zhang X., Deng J., Wang H., Hirsch F.R.,Zhou C. Galectin-9 in non-small cell lung cancer. Lung Cancer, 2019, Vol.136, no, pp. 80-85. [10.1016/j.lungcan.2019.08.014] https://www.ncbi.nlm.nih.gov/pubmed/31454748Test; He Y., Rivard C.J., Rozeboom L., Yu H., Ellison K., Kowalewski A., Zhou C.,Hirsch F.R. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci, 2016, Vol.107, no 9, pp. 1193-7. [10.1111/cas.12986] https://www.ncbi.nlm.nih.gov/pubmed/27297395Test; Hemon P., Jean-Louis F., Ramgolam K., Brignone C., Viguier M., Bachelez H., Triebel F., Charron D., Aoudjit F., Al-Daccak R.,Michel L. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol, 2011, Vol.186, no 9, pp. 5173-83. [10.4049/jimmunol.1002050] https://www.ncbi.nlm.nih.gov/pubmed/21441454Test; Henry L., Vervier J., Boucher A., Brichant G., Gaspard O., Labied S., Munaut C., Ravet S.,Nisolle M. Oocyte Cryopreservation in Patients with Endometriosis: Current Knowledge and Number Needed to Treat. J Clin Med, 2022, Vol.11, no 15. [10.3390/jcm11154559] https://www.ncbi.nlm.nih.gov/pubmed/35956174Test; Hong J.H., Cho H.W., Ouh Y.T., Lee J.K.,Chun Y. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer. J Gynecol Oncol, 2023, Vol.34, no 2, pp. e18. [10.3802/jgo.2023.34.e18] https://www.ncbi.nlm.nih.gov/pubmed/36509464Test; Huang R.Y., Francois A., McGray A.R., Miliotto A.,Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology, 2017, Vol.6, no 1, pp. e1249561. [10.1080/2162402X.2016.1249561] https://www.ncbi.nlm.nih.gov/pubmed/28197366Test; Huo J.L., Wang Y.T., Fu W.J., Lu N.,Liu Z.S. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol, 2022, Vol.13, no, pp. 956090. [10.3389/fimmu.2022.956090] https://www.ncbi.nlm.nih.gov/pubmed/35958563Test; Incognito G.G., Di Guardo F., Gulino F.A., Genovese F., Benvenuto D., Lello C.,Palumbo M. Interleukin-6 as A Useful Predictor of Endometriosis-Associated Infertility: A Systematic Review. Int J Fertil Steril, 2023, Vol.17, no 4, pp. 226-230. [10.22074/ijfs.2023.557683.1329] https://www.ncbi.nlm.nih.gov/pubmed/37577903Test; Jansa V., Pusic Novak M., Ban Frangez H.,Rizner T.L. TGFBI as a candidate biomarker for non-invasive diagnosis of early-stage endometriosis. Hum Reprod, 2023, Vol.38, no 7, pp. 1284-1296. [10.1093/humrep/dead091] https://www.ncbi.nlm.nih.gov/pubmed/37187159Test; Jarollahi S., Chaichian S., Jarollahi A., Hajmohammadi R., Mashayekhi R., Shahmohammadi F., Eslamivaghar M.,Ghasemi Z. The Diagnostic Accuracy of Galectin-9 for Diagnosis of Endometriosis in Comparison with Laparoscopy. J Reprod Infertil, 2022, Vol.23, no 4, pp. 271-278. [10.18502/jri.v23i4.10812] https://www.ncbi.nlm.nih.gov/pubmed/36452187Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674464/pdf/JRI-23-271.pdfTest; Jeung I., Cheon K.,Kim M.R. Decreased Cytotoxicity of Peripheral and Peritoneal Natural Killer Cell in Endometriosis. Biomed Res Int, 2016, Vol.2016, no, pp. 2916070. [10.1155/2016/2916070] https://www.ncbi.nlm.nih.gov/pubmed/27294113Test; Jiang J., Jiang Z.,Xue M. Serum and peritoneal fluid levels of interleukin-6 and interleukin-37 as biomarkers for endometriosis. Gynecol Endocrinol, 2019, Vol.35, no 7, pp. 571-575. [10.1080/09513590.2018.1554034] https://www.ncbi.nlm.nih.gov/pubmed/30632819Test; Jolicoeur C., Boutouil M., Drouin R., Paradis I., Lemay A.,Akoum A. Increased expression of monocyte chemotactic protein-1 in the endometrium of women with endometriosis. Am J Pathol, 1998, Vol.152, no 1, pp. 125-33. https://www.ncbi.nlm.nih.gov/pubmed/9422530Test; Kang C. Retifanlimab: First Approval. Drugs, 2023, Vol.83, no 8, pp. 731-737. [10.1007/s40265-023-01884-7] https://www.ncbi.nlm.nih.gov/pubmed/37184754Test; Kang Y.J., Jeung I.C., Park A., Park Y.J., Jung H., Kim T.D., Lee H.G., Choi I.,Yoon S.R. An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod, 2014, Vol.29, no 10, pp. 2176-89. [10.1093/humrep/deu172] http://www.ncbi.nlm.nih.gov/pubmed/25035432Test; Kaya C., Alay I., Guraslan H., Gedikbasi A., Ekin M., Ertas Kaya S., Oral E.,Yasar L. The Role of Serum Caspase 3 Levels in Prediction of Endometriosis Severity. Gynecol Obstet Invest, 2018, Vol.83, no 6, pp. 576-585. [10.1159/000489494] https://www.ncbi.nlm.nih.gov/pubmed/30071521Test; Keir M.E., Butte M.J., Freeman G.J.,Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008, Vol.26, no, pp. 677-704. [10.1146/annurev.immunol.26.021607.090331] https://www.ncbi.nlm.nih.gov/pubmed/18173375Test; Kimber-Trojnar Z., Pilszyk A., Niebrzydowska M., Pilszyk Z., Ruszala M.,Leszczynska-Gorzelak B. The Potential of Non-Invasive Biomarkers for Early Diagnosis of Asymptomatic Patients with Endometriosis. J Clin Med, 2021, Vol.10, no 13. [10.3390/jcm10132762] https://www.ncbi.nlm.nih.gov/pubmed/34201813Test; Kong F., Jin M., Cao D., Jia Z., Liu Y.,Jiang J. Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma. PeerJ, 2020, Vol.8, no, pp. e9949. [10.7717/peerj.9949] https://www.ncbi.nlm.nih.gov/pubmed/32995093Test; Kovalak E.E., Karacan T., Zengi O., Karabay Akgul O., Ozyurek S.E.,Guraslan H. Evaluation of new biomarkers in stage III and IV endometriosis. Gynecol Endocrinol, 2023, Vol.39, no 1, pp. 2217290. [10.1080/09513590.2023.2217290] https://www.ncbi.nlm.nih.gov/pubmed/37236244Test; Krummel M.F.,Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med, 1995, Vol.182, no 2, pp. 459-65. [10.1084/jem.182.2.459] https://www.ncbi.nlm.nih.gov/pubmed/7543139Test; Laudanski P., Rogalska G., Warzecha D., Lipa M., Manka G., Kiecka M., Spaczynski R., Piekarski P., Banaszewska B., Jakimiuk A., Issat T., Rokita W., Mlodawski J., Szubert M., Sieroszewski P., Raba G., Szczupak K., Kluz T., Kluza M., Neuman T., Adler P., Peterson H., Salumets A.,Wielgos M. Autoantibody screening of plasma and peritoneal fluid of patients with endometriosis. Hum Reprod, 2023, Vol.38, no 4, pp. 629-643. [10.1093/humrep/dead011] https://www.ncbi.nlm.nih.gov/pubmed/36749097Test; Lee M.Y., Kim S.H., Oh Y.S., Heo S.H., Kim K.H., Chae H.D., Kim C.H.,Kang B.M. Role of interleukin-32 in the pathogenesis of endometriosis: in vitro, human and transgenic mouse data. Hum Reprod, 2018, Vol.33, no 5, pp. 807-816. [10.1093/humrep/dey055] https://www.ncbi.nlm.nih.gov/pubmed/29562285Test; Li C., Zhou J., Shao J., Yuan L., Cheng Q., Wang L.,Duan Z. Decrease in CD226 expression on CD4(+) T cells in patients with endometriosis. Biosci Trends, 2023, Vol.17, no 2, pp. 168-171. [10.5582/bst.2022.01501] https://www.ncbi.nlm.nih.gov/pubmed/37081668Test; Li J., Yan S., Li Q., Huang Y., Ji M., Jiao X., Yuan M.,Wang G. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis. Mol Hum Reprod, 2022, Vol.28, no 5. [10.1093/molehr/gaac010] https://www.ncbi.nlm.nih.gov/pubmed/35404426Test; Li Y., Zhang J., Zhang D., Hong X., Tao Y., Wang S., Xu Y., Piao H., Yin W., Yu M., Zhang Y., Fu Q., Li D., Chang X.,Du M. Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss. Sci Signal, 2017, Vol.10, no 498. [10.1126/scisignal.aah4323] https://www.ncbi.nlm.nih.gov/pubmed/28951537Test; Liu Q., Ma P., Liu L., Ma G., Ma J., Liu X., Liu Y., Lin W.,Zhu Y. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model. Eur J Pharm Sci, 2017, Vol.96, no, pp. 542-550. [10.1016/j.ejps.2016.10.031] https://www.ncbi.nlm.nih.gov/pubmed/27989857Test; Lozano E., Dominguez-Villar M., Kuchroo V.,Hafler D.A. The TIGIT/CD226 axis regulates human T cell function. J Immunol, 2012, Vol.188, no 8, pp. 3869-75. [10.4049/jimmunol.1103627] https://www.ncbi.nlm.nih.gov/pubmed/22427644Test; Mahnke K.,Enk A.H. TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention. J Invest Dermatol, 2016, Vol.136, no 1, pp. 9-11. [10.1016/j.jid.2015.10.048] https://www.ncbi.nlm.nih.gov/pubmed/26763417Test; Man Y., Dai C., Guo Q., Jiang L.,Shi Y. A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer. Discov Oncol, 2023, Vol.14, no 1, pp. 59. [10.1007/s12672-023-00669-4] https://www.ncbi.nlm.nih.gov/pubmed/37154982Test; Martin-Liberal J., Kordbacheh T.,Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf, 2015, Vol.14, no 6, pp. 957-64. [10.1517/14740338.2015.1021774] https://www.ncbi.nlm.nih.gov/pubmed/25927979Test; Martire F.G., Russo C., Selntigia A., Nocita E., Soreca G., Lazzeri L., Zupi E.,Exacoustos C. Early noninvasive diagnosis of endometriosis: dysmenorrhea and specific ultrasound findings are important indicators in young women. Fertil Steril, 2023, Vol.119, no 3, pp. 455-464. [10.1016/j.fertnstert.2022.12.004] https://www.ncbi.nlm.nih.gov/pubmed/36493871Test; Maruhashi T., Sugiura D., Okazaki I.M.,Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer, 2020, Vol.8, no 2. [10.1136/jitc-2020-001014] https://www.ncbi.nlm.nih.gov/pubmed/32929051Test; Matalliotakis I., Neonaki M., Zolindaki A., Hassan E., Georgoulias V.,Koumantakis E. Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Int J Fertil Womens Med, 1997, Vol.42, no 3, pp. 211-4. https://www.ncbi.nlm.nih.gov/pubmed/9222806Test; Matsubara E., Shinchi Y., Komohara Y., Yano H., Pan C., Fujiwara Y., Ikeda K.,Suzuki M. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma. Med Mol Morphol, 2023 no. [10.1007/s00795-023-00361-0] https://www.ncbi.nlm.nih.gov/pubmed/37402054Test; Meggyes M., Szereday L., Bohonyi N., Koppan M., Szegedi S., Marics-Kutas A., Marton M., Totsimon A.,Polgar B. Different Expression Pattern of TIM-3 and Galectin-9 Molecules by Peripheral and Peritoneal Lymphocytes in Women with and without Endometriosis. Int J Mol Sci, 2020, Vol.21, no 7. [10.3390/ijms21072343] https://www.ncbi.nlm.nih.gov/pubmed/32231038Test; https://mdpi-res.com/d_attachment/ijms/ijms-21-02343/article_deploy/ijms-21-02343-v2.pdf?version=1585549834Test; Mikus M., Goldstajn M.S., Brlecic I., Dumancic S., Lagana A.S., Chiantera V., Vujic G.,Coric M. CTLA4-Linked Autoimmunity in the Pathogenesis of Endometriosis and Related Infertility: A Systematic Review. Int J Mol Sci, 2022, Vol.23, no 18. [10.3390/ijms231810902] https://www.ncbi.nlm.nih.gov/pubmed/36142815Test; Motamedi M., Shahbaz S., Fu L., Dunsmore G., Xu L., Harrington R., Houston S.,Elahi S. Galectin-9 Expression Defines a Subpopulation of NK Cells with Impaired Cytotoxic Effector Molecules but Enhanced IFN-gamma Production, Dichotomous to TIGIT, in HIV-1 Infection. Immunohorizons, 2019, Vol.3, no 11, pp. 531-546. [10.4049/immunohorizons.1900087] https://www.ncbi.nlm.nih.gov/pubmed/31732662Test; Muharam R., Bustami A., Gusti Mansur I., Zulkifli Jacoeb T., Giustiniani J., Schiavon V.,Bensussan A. Cytotoxic activity of peripheral blood mononuclear cells in patients with endometriosis: A cross-sectional study. Int J Reprod Biomed, 2022, Vol.20, no 8, pp. 691-700. [10.18502/ijrm.v20i8.11758] https://www.ncbi.nlm.nih.gov/pubmed/36313261Test; Murakami D., Matsuda K., Iwamoto H., Mitani Y., Mizumoto Y., Nakamura Y., Matsuzaki I., Iwamoto R., Takahashi Y., Kojima F., Murata S.I.,Yamaue H. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. PLoS One, 2022, Vol.17, no 3, pp. e0265908. [10.1371/journal.pone.0265908] https://www.ncbi.nlm.nih.gov/pubmed/35324958Test; Mutti L., Valle M.T., Balbi B., Orengo A.M., Lazzaro A., Alciato P., Gatti E., Betta P.G.,Pozzi E. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer, 1998, Vol.78, no 6, pp. 740-9. [10.1002/(sici)1097-0215(19981209)78:63.0.co;2-5] https://www.ncbi.nlm.nih.gov/pubmed/9833768Test; Naseri S., Rosenberg-Hasson Y., Maecker H.T., Avrutsky M.I.,Blumenthal P.D. A cross-sectional study comparing the inflammatory profile of menstrual effluent vs. peripheral blood. Health Sci Rep, 2023, Vol.6, no 1, pp. e1038. [10.1002/hsr2.1038] https://www.ncbi.nlm.nih.gov/pubmed/36620506Test; Nasr S., Haddad F.G., Khazen J., Kattan J.,Trak-Smayra V. PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience. BMC Cancer, 2023, Vol.23, no 1, pp. 817. [10.1186/s12885-023-11299-y] https://www.ncbi.nlm.nih.gov/pubmed/37658290Test; Neumann M., Murphy N.,Seetharamu N. The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab. Cancer Med J, 2022, Vol.5, no 1, pp. 31-45. https://www.ncbi.nlm.nih.gov/pubmed/35253011Test; Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M.,Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res, 2007, Vol.13, no 7, pp. 2151-7. [10.1158/1078-0432.CCR-06-2746] https://www.ncbi.nlm.nih.gov/pubmed/17404099Test; Oksasoglu B., Hepokur C., Misir S., Yildiz C., Sonmez G.,Yanik A. Determination of PD-1 expression in peripheral blood cells in patients with endometriosis. Gynecol Endocrinol, 2021, Vol.37, no 2, pp. 157-161. [10.1080/09513590.2020.1821358] https://www.ncbi.nlm.nih.gov/pubmed/33078970Test; Olkowska-Truchanowicz J., Bialoszewska A., Zwierzchowska A., Sztokfisz-Ignasiak A., Janiuk I., Dabrowski F., Korczak-Kowalska G., Barcz E., Bocian K.,Malejczyk J. Peritoneal Fluid from Patients with Ovarian Endometriosis Displays Immunosuppressive Potential and Stimulates Th2 Response. Int J Mol Sci, 2021, Vol.22, no 15. [10.3390/ijms22158134] https://www.ncbi.nlm.nih.gov/pubmed/34360900Test; Ortiz C.N., Torres-Reveron A.,Appleyard C.B. Metabolomics in endometriosis: challenges and perspectives for future studies. Reprod Fertil, 2021, Vol.2, no 2, pp. R35-R50. [10.1530/RAF-20-0047] https://www.ncbi.nlm.nih.gov/pubmed/35128453Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812441/pdf/RAF-20-0047.pdfTest; Othman Eel D., Hornung D., Salem H.T., Khalifa E.A., El-Metwally T.H.,Al-Hendy A. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol, 2008, Vol.137, no 2, pp. 240-6. [10.1016/j.ejogrb.2007.05.001] https://www.ncbi.nlm.nih.gov/pubmed/17582674Test; Othman E.R., Hornung D., Hussein M., Abdelaal, II, Sayed A.A., Fetih A.N.,Al-Hendy A. Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients. Eur J Obstet Gynecol Reprod Biol, 2016, Vol.200, no, pp. 1-5. [10.1016/j.ejogrb.2016.02.025] https://www.ncbi.nlm.nih.gov/pubmed/26963895Test; Oyama R., Kanayama M., Mori M., Matsumiya H., Taira A., Shinohara S., Takenaka M., Yoneda K., Kuroda K.,Tanaka F. CD155 expression and its clinical significance in non-small cell lung cancer. Oncol Lett, 2022, Vol.23, no 5, pp. 166. [10.3892/ol.2022.13286] https://www.ncbi.nlm.nih.gov/pubmed/35414831Test; Pan H.Y.,Wan J. Serum HSF1 is upregulated in endometriosis patients and serves as a potential diagnostic biomarker. Kaohsiung J Med Sci, 2023, Vol.39, no 10, pp. 1045-1051. [10.1002/kjm2.12723] https://www.ncbi.nlm.nih.gov/pubmed/37409787Test; Popovici R.M., Krause M.S., Germeyer A., Strowitzki T.,von Wolff M. Galectin-9: a new endometrial epithelial marker for the mid- and late-secretory and decidual phases in humans. J Clin Endocrinol Metab, 2005, Vol.90, no 11, pp. 6170-6. [10.1210/jc.2004-2529] https://www.ncbi.nlm.nih.gov/pubmed/16105962Test; Qi H., Li Y., Liu X., Jiang Y., Li Z., Xu X., Zhang H.,Hu X. Tim-3 regulates the immunosuppressive function of decidual MDSCs via the Fyn-STAT3-C/EBPbeta pathway during Toxoplasma gondii infection. PLoS Pathog, 2023, Vol.19, no 4, pp. e1011329. [10.1371/journal.ppat.1011329] https://www.ncbi.nlm.nih.gov/pubmed/37058540Test; Raschi E., Comito F., Massari F.,Gelsomino F. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy, 2023, Vol.15, no 2, pp. 85-91. [10.2217/imt-2022-0172] https://www.ncbi.nlm.nih.gov/pubmed/36628573Test; Rondon L., Fu R.,Patel M.R. Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma. Cancers (Basel), 2023, Vol.15, no 11. [10.3390/cancers15112940] https://www.ncbi.nlm.nih.gov/pubmed/37296902Test; Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res, 2019, Vol.38, no 1, pp. 255. [10.1186/s13046-019-1259-z] https://www.ncbi.nlm.nih.gov/pubmed/31196207Test; Sansone A.M., Hisrich B.V., Young R.B., Abel W.F., Bowens Z., Blair B.B., Funkhouser A.T., Schammel D.P., Green L.J., Lessey B.A.,Blenda A.V. Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis. Curr Issues Mol Biol, 2021, Vol.43, no 3, pp. 1350-1360. [10.3390/cimb43030096] https://www.ncbi.nlm.nih.gov/pubmed/34698105Test; Santoso B., Sa'adi A., Dwiningsih S.R., Tunjungseto A., Widyanugraha M.Y.A., Mufid A.F., Rahmawati N.Y.,Ahsan F. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility. Am J Reprod Immunol, 2020, Vol.84, no 4, pp. e13296. [10.1111/aji.13296] https://www.ncbi.nlm.nih.gov/pubmed/32593225Test; Shafrir A.L., Farland L.V., Shah D.K., Harris H.R., Kvaskoff M., Zondervan K.,Missmer S.A. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol, 2018, Vol.51, no, pp. 1-15. [10.1016/j.bpobgyn.2018.06.001] https://www.ncbi.nlm.nih.gov/pubmed/30017581Test; Shah M., Osgood C.L., Amatya A.K., Fiero M.H., Pierce W.F., Nair A., Herz J., Robertson K.J., Mixter B.D., Tang S., Pazdur R., Beaver J.A.,Amiri-Kordestani L. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res, 2022, Vol.28, no 24, pp. 5249-5253. [10.1158/1078-0432.CCR-22-1110] https://www.ncbi.nlm.nih.gov/pubmed/35925043Test; Shigesi N., Kvaskoff M., Kirtley S., Feng Q., Fang H., Knight J.C., Missmer S.A., Rahmioglu N., Zondervan K.T.,Becker C.M. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update, 2019, Vol.25, no 4, pp. 486-503. [10.1093/humupd/dmz014] https://www.ncbi.nlm.nih.gov/pubmed/31260048Test; Simone R., Pesce G., Antola P., Rumbullaku M., Bagnasco M., Bizzaro N.,Saverino D. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int, 2014, Vol.2014, no, pp. 215763. [10.1155/2014/215763] https://www.ncbi.nlm.nih.gov/pubmed/24605322Test; Souza D.S., Macheroni C., Pereira G.J.S., Vicente C.M.,Porto C.S. Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor. Front Endocrinol (Lausanne), 2023, Vol.14, no, pp. 1124111. [10.3389/fendo.2023.1124111] https://www.ncbi.nlm.nih.gov/pubmed/36936148Test; Stanietsky N., Simic H., Arapovic J., Toporik A., Levy O., Novik A., Levine Z., Beiman M., Dassa L., Achdout H., Stern-Ginossar N., Tsukerman P., Jonjic S.,Mandelboim O. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A, 2009, Vol.106, no 42, pp. 17858-63. [10.1073/pnas.0903474106] https://www.ncbi.nlm.nih.gov/pubmed/19815499Test; Stasenko M., Smith E., Yeku O., Park K.J., Laster I., Lee K., Walderich S., Spriggs E., Rueda B., Weigelt B., Zamarin D., Rao T.D.,Spriggs D.R. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Sci Rep, 2021, Vol.11, no 1, pp. 3718. [10.1038/s41598-021-82686-3] https://www.ncbi.nlm.nih.gov/pubmed/33580170Test; Suszczyk D., Skiba W., Zardzewialy W., Pawlowska A., Wlodarczyk K., Polak G., Tarkowski R.,Wertel I. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis. Int J Mol Sci, 2022, Vol.23, no 19. [10.3390/ijms231911607] https://www.ncbi.nlm.nih.gov/pubmed/36232911Test; https://mdpi-res.com/d_attachment/ijms/ijms-23-11607/article_deploy/ijms-23-11607-v2.pdf?version=1665309498Test; Suzman D.L., Agrawal S., Ning Y.M., Maher V.E., Fernandes L.L., Karuri S., Tang S., Sridhara R., Schroeder J., Goldberg K.B., Ibrahim A., McKee A.E., Pazdur R.,Beaver J.A. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Oncologist, 2019, Vol.24, no 4, pp. 563-569. [10.1634/theoncologist.2018-0084] https://www.ncbi.nlm.nih.gov/pubmed/30541754Test; Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J, 2014, Vol.20, no 4, pp. 290-5. [10.1097/PPO.0000000000000056] https://www.ncbi.nlm.nih.gov/pubmed/25098290Test; Tahermanesh K., Hakimpour S., Govahi A., Rokhgireh S., Mehdizadeh M., Minaeian S., Barati M., Chaichian S., Kashi A.M., Nassiri S., Eslahi N., Ajdary M.,Ahmadi M. Evaluation of expression of biomarkers of PLAGL1 (ZAC1), microRNA, and their non-coding RNAs in patients with endometriosis. J Gynecol Obstet Hum Reprod, 2023, Vol.52, no 4, pp. 102568. [10.1016/j.jogoh.2023.102568] https://www.ncbi.nlm.nih.gov/pubmed/36868502Test; Tanaka E., Sendo F., Kawagoe S.,Hiroi M. Decreased natural killer cell activity in women with endometriosis. Gynecol Obstet Invest, 1992, Vol.34, no 1, pp. 27-30. [10.1159/000292720] https://www.ncbi.nlm.nih.gov/pubmed/1526528Test; Tang T., Lai H., Huang X., Gu L.,Shi H. Application of serum markers in diagnosis and staging of ovarian endometriosis. J Obstet Gynaecol Res, 2021, Vol.47, no 4, pp. 1441-1450. [10.1111/jog.14654] https://www.ncbi.nlm.nih.gov/pubmed/33448139Test; Tella S.H., Kommalapati A., Mahipal A.,Jin Z. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines, 2022, Vol.10, no 6. [10.3390/biomedicines10061304] https://www.ncbi.nlm.nih.gov/pubmed/35740326Test; Timmerman J., Herbaux C., Ribrag V., Zelenetz A.D., Houot R., Neelapu S.S., Logan T., Lossos I.S., Urba W., Salles G., Ramchandren R., Jacobson C., Godwin J., Carpio C., Lathers D., Liu Y., Neely J., Suryawanshi S., Koguchi Y.,Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol, 2020, Vol.95, no 5, pp. 510-520. [10.1002/ajh.25757] https://www.ncbi.nlm.nih.gov/pubmed/32052473Test; Vellanki P.J., Mulkey F., Jaigirdar A.A., Rodriguez L., Wang Y., Xu Y., Zhao H., Liu J., Howe G., Wang J., Choo Q., Golding S.J., Mansell V., Korsah K., Spillman D., de Claro R.A., Pazdur R., Beaver J.A.,Singh H. FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. Clin Cancer Res, 2021, Vol.27, no 13, pp. 3522-3527. [10.1158/1078-0432.CCR-20-4338] https://www.ncbi.nlm.nih.gov/pubmed/33632925Test; Vence L., Bucktrout S.L., Fernandez Curbelo I., Blando J., Smith B.M., Mahne A.E., Lin J.C., Park T., Pascua E., Sai T., Chaparro-Riggers J., Subudhi S.K., Scutti J.B., Higa M.G., Zhao H., Yadav S.S., Maitra A., Wistuba, II, Allison J.P.,Sharma P. Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res, 2019, Vol.25, no 21, pp. 6501-6510. [10.1158/1078-0432.CCR-19-0289] https://www.ncbi.nlm.nih.gov/pubmed/31358539Test; Villanacci R., Bandini V., Ottolina J., Pagliardini L., Candiani M.,Vigano P. The pathogenesis of endometriosis: clues from the immunological evidence. Minerva Obstet Gynecol, 2021, Vol.73, no 3, pp. 275-282. [10.23736/S2724-606X.21.04768-7] https://www.ncbi.nlm.nih.gov/pubmed/34008382Test; Vinay D.S.,Kwon B.S. 4-1BB signaling beyond T cells. Cell Mol Immunol, 2011, Vol.8, no 4, pp. 281-4. [10.1038/cmi.2010.82] http://www.ncbi.nlm.nih.gov/pubmed/21217771Test; http://www.nature.com/cmi/journal/v8/n4/pdf/cmi201082a.pdfTest; von Euw E., Chodon T., Attar N., Jalil J., Koya R.C., Comin-Anduix B.,Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med, 2009, Vol.7, no, pp. 35. [10.1186/1479-5876-7-35] https://www.ncbi.nlm.nih.gov/pubmed/19457253Test; Walankiewicz M., Grywalska E., Polak G., Korona-Glowniak I., Witt E., Surdacka A., Kotarski J.,Rolinski J. The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters. Mediators Inflamm, 2018, Vol.2018, no, pp. 7041342. [10.1155/2018/7041342] https://www.ncbi.nlm.nih.gov/pubmed/30595667Test; Wang X.B., Fan Z.Z., Anton D., Vollenhoven A.V., Ni Z.H., Chen X.F.,Lefvert A.K. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol, 2011, Vol.12, no, pp. 21. [10.1186/1471-2172-12-21] https://www.ncbi.nlm.nih.gov/pubmed/21414236Test; Wang Y., Du J., Gao Z., Sun H., Mei M., Wang Y., Ren Y.,Zhou X. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer, 2023, Vol.128, no 7, pp. 1196-1207. [10.1038/s41416-022-02084-y] https://www.ncbi.nlm.nih.gov/pubmed/36522474Test; Wang Y., Feng T., Li H., Xiong Y.,Tao Y. Gal-9/Tim-3 signaling pathway activation suppresses the generation of Th17 cells and promotes the induction of Foxp3(+) regulatory T cells in renal ischemia-reperfusion injury. Mol Immunol, 2023, Vol.156, no, pp. 136-147. [10.1016/j.molimm.2023.03.008] https://www.ncbi.nlm.nih.gov/pubmed/36921488Test; Warzecha D., Zalecka J., Manka G., Kiecka M., Lipa M., Spaczynski R., Piekarski P., Banaszewska B., Jakimiuk A., Issat T., Rokita W., Mlodawski J., Szubert M., Sieroszewski P., Raba G., Szczupak K., Kluz T., Kluza M., Wielgos M., Oldak L., Lesniewska A., Gorodkiewicz E.,Laudanski P. Plasma and Peritoneal Fluid Fibronectin and Collagen IV Levels as Potential Biomarkers of Endometriosis. Int J Mol Sci, 2022, Vol.23, no 24. [10.3390/ijms232415669] https://www.ncbi.nlm.nih.gov/pubmed/36555313Test; Wessels J.M., Kay V.R., Leyland N.A., Agarwal S.K.,Foster W.G. Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis. Fertil Steril, 2016, Vol.105, no 1, pp. 119-28 e1-5. [10.1016/j.fertnstert.2015.09.003] https://www.ncbi.nlm.nih.gov/pubmed/26409150Test; Wiles K.N., Tsikretsis L.E., Alioto C.M., Hermida de Viveiros P.A., Villaflor V.M.,Tetreault M.P. GITR agonistic stimulation enhances the anti-tumor immune response in a mouse model of ESCC. Carcinogenesis, 2022, Vol.43, no 9, pp. 908-918. [10.1093/carcin/bgac064] https://www.ncbi.nlm.nih.gov/pubmed/35880612Test; Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T.,Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, Vol.322, no 5899, pp. 271-5. [10.1126/science.1160062] http://www.ncbi.nlm.nih.gov/pubmed/18845758Test; Wroblewski J.M., Bixby D.L., Borowski C.,Yannelli J.R. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer, 2001, Vol.33, no 2-3, pp. 181-94. [10.1016/s0169-5002(01)00210-0] https://www.ncbi.nlm.nih.gov/pubmed/11551413Test; Wu L., Lv C., Su Y., Li C., Zhang H., Zhao X.,Li M. Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. Gynecol Endocrinol, 2019, Vol.35, no 3, pp. 251-256. [10.1080/09513590.2018.1519787] https://www.ncbi.nlm.nih.gov/pubmed/30325236Test; Xu F., Liu J., Liu D., Liu B., Wang M., Hu Z., Du X., Tang L.,He F. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res, 2014, Vol.74, no 13, pp. 3418-28. [10.1158/0008-5472.CAN-13-2690] https://www.ncbi.nlm.nih.gov/pubmed/24769443Test; Xu J.X., Maher V.E., Zhang L., Tang S., Sridhara R., Ibrahim A., Kim G.,Pazdur R. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. Oncologist, 2017, Vol.22, no 3, pp. 311-317. [10.1634/theoncologist.2016-0476] https://www.ncbi.nlm.nih.gov/pubmed/28232599Test; Xue C., Zhu D., Chen L., Xu Y., Xu B., Zhang D.,Jiang J. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer. Transl Cancer Res, 2019, Vol.8, no 1, pp. 111-119. [10.21037/tcr.2019.01.09] https://www.ncbi.nlm.nih.gov/pubmed/35116740Test; Yamashita S., Hashimoto K., Sawada I., Ogawa M., Nakatsuka E., Kawano M., Kinose Y., Kodama M., Sawada K.,Kimura T. Endometrial galectin-3 causes endometriosis by supporting eutopic endometrial cell survival and engraftment in the peritoneal cavity. Am J Reprod Immunol, 2022, Vol.87, no 6, pp. e13533. [10.1111/aji.13533] https://www.ncbi.nlm.nih.gov/pubmed/35366371Test; Yan J., Zhang Y., Zhang J.P., Liang J., Li L.,Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PLoS One, 2013, Vol.8, no 3, pp. e58006. [10.1371/journal.pone.0058006] https://www.ncbi.nlm.nih.gov/pubmed/23526963Test; Yang M., Yu Q., Liu J., Fu W., Cao Y., Yu L., Shao S., Wang X., Niu H.,Wang Y. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. J Surg Oncol, 2015, Vol.112, no 4, pp. 430-5. [10.1002/jso.24012] https://www.ncbi.nlm.nih.gov/pubmed/26265374Test; Yasinska I.M., Sakhnevych S.S., Pavlova L., Teo Hansen Selno A., Teuscher Abeleira A.M., Benlaouer O., Goncalves Silva I., Mosimann M., Varani L., Bardelli M., Hussain R., Siligardi G., Cholewa D., Berger S.M., Gibbs B.F., Ushkaryov Y.A., Fasler-Kan E., Klenova E.,Sumbayev V.V. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Front Immunol, 2019, Vol.10, no, pp. 1594. [10.3389/fimmu.2019.01594] https://www.ncbi.nlm.nih.gov/pubmed/31354733Test; Yildiz C., Caner A., Oksasoglu B., Misir S., Yaylim I.,Hepokur C. The role of cytokeratin 19 levels in the determination of endometriosis stages. Gynecol Endocrinol, 2022, Vol.38, no 10, pp. 879-884. [10.1080/09513590.2022.2120606] https://www.ncbi.nlm.nih.gov/pubmed/36068968Test; Zhang C., Xu L., Ma Y., Huang Y., Zhou L., Le H.,Chen Z. Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study. J Thorac Dis, 2023, Vol.15, no 3, pp. 1433-1444. [10.21037/jtd-23-227] https://www.ncbi.nlm.nih.gov/pubmed/37065598Test; Zhang Y., Wu L., Wen X.,Lv X. Identification and validation of risk score model based on gene set activity as a diagnostic biomarker for endometriosis. Heliyon, 2023, Vol.9, no 7, pp. e18277. [10.1016/j.heliyon.2023.e18277] https://www.ncbi.nlm.nih.gov/pubmed/37539146Test; Zhang Y., Yang R., Xu C., Zhang Y., Deng M., Wu D., Tang F., Liu X., Han Y., Zhan Y.,Miao J. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy. Pathol Res Pract, 2022, Vol.236, no, pp. 153990. [10.1016/j.prp.2022.153990] https://www.ncbi.nlm.nih.gov/pubmed/35749914Test; Zhang Y., Yao Q., Pan Y., Fang X., Xu H., Zhao T., Zhu G., Jiang T., Li S.,Cao H. Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. Cancers (Basel), 2023, Vol.15, no 3. [10.3390/cancers15030682] https://www.ncbi.nlm.nih.gov/pubmed/36765640Test; Zhang Y., Zhang H., Wei M., Mou T., Shi T., Ma Y., Cai X., Li Y., Dong J.,Wei J. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8(+) T Cells in HCC. Mol Ther, 2019, Vol.27, no 11, pp. 1906-1918. [10.1016/j.ymthe.2019.07.019] https://www.ncbi.nlm.nih.gov/pubmed/31466933Test; Zhang Y.,Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol, 2020, Vol.1248, no, pp. 201-226. [10.1007/978-981-15-3266-5_9] https://www.ncbi.nlm.nih.gov/pubmed/32185712Test; Zheng D., Hou X., Yu J.,He X. Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. Front Pharmacol, 2022, Vol.13, no, pp. 928369. [10.3389/fphar.2022.928369] https://www.ncbi.nlm.nih.gov/pubmed/35935874Test; Zheng L., Sun D.F.,Tong Y. Exosomal miR-202 derived from leukorrhea as a potential biomarker for endometriosis. J Int Med Res, 2023, Vol.51, no 1, pp. 3000605221147183. [10.1177/03000605221147183] https://www.ncbi.nlm.nih.gov/pubmed/36597409Test; Zhou E., Huang Q., Wang J., Fang C., Yang L., Zhu M., Chen J., Chen L.,Dong M. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol, 2015, Vol.8, no 7, pp. 8018-27. https://www.ncbi.nlm.nih.gov/pubmed/26339368Test; Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B.,Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 2005, Vol.6, no 12, pp. 1245-52. [10.1038/ni1271] https://www.ncbi.nlm.nih.gov/pubmed/16286920Test; Zhu H., Wang M., Du Y., Liu X., Weng X.,Li C. 4-1BBL has a Possible Role in Mediating Castration-Resistant Conversion of Prostate Cancer via Up-Regulation of Androgen Receptor. J Cancer, 2019, Vol.10, no 11, pp. 2464-2471. [10.7150/jca.29648] https://www.ncbi.nlm.nih.gov/pubmed/31258752Test; Ziogas I.A., Evangeliou A.P., Giannis D., Hayat M.H., Mylonas K.S., Tohme S., Geller D.A., Elias N., Goyal L.,Tsoulfas G. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist, 2021, Vol.26, no 6, pp. e1036-e1049. [10.1002/onco.13638] https://www.ncbi.nlm.nih.gov/pubmed/33314549Test; https://www.mimmun.ru/mimmun/article/view/2923Test

الإتاحة: https://doi.org/10.15789/1563-0625-CIT-2923Test
https://doi.org/10.15789/1563-0625-0-0Test
https://www.mimmun.ru/mimmun/article/view/2923Test

المؤلفون: Li, Yu-Quan, Chen, Xue-Mei, Si, Gui-Fei, Yuan, Xue-Min

المصدر: Biomolecules and Biomedicine; Advanced online ; 2831-090X ; 2831-0896

مصطلحات موضوعية: Immunotherapy, programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand 1 (PD-L1), lymphocyte activation gene-3 (LAG-3), combination therapy

وصف الملف: application/pdf

العلاقة: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10339/3222Test; https://www.bjbms.org/ojs/index.php/bjbms/article/view/10339Test

الإتاحة: https://doi.org/10.17305/bb.2024.10339Test
https://www.bjbms.org/ojs/index.php/bjbms/article/view/10339Test

المؤلفون: Jingjing Su, Yiting Fu, Zitong Cui, Zain Abidin, Jingsong Yuan, Xinmiao Zhang, Runmin Li, Chunzhen Zhao

المصدر: Frontiers in Pharmacology, Vol 14 (2024)

مصطلحات موضوعية: relatlimab, LAG-3 inhibitor, nivolumab, metastatic melanoma, immune checkpoint, Therapeutics. Pharmacology, RM1-950

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1349081/fullTest; https://doaj.org/toc/1663-9812Test; https://doaj.org/article/1d2b0ae21c3643408d076b9b33d7a148Test

الإتاحة: https://doi.org/10.3389/fphar.2023.1349081Test
https://doaj.org/article/1d2b0ae21c3643408d076b9b33d7a148Test

المؤلفون: Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu

المصدر: Thoracic Cancer, Vol 15, Iss 1, Pp 3-14 (2024)

مصطلحات موضوعية: DLL3, immunotherapy, LAG‐3, small cell lung cancer, TIGIT, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

العلاقة: https://doi.org/10.1111/1759-7714.15178Test; https://doaj.org/toc/1759-7706Test; https://doaj.org/toc/1759-7714Test; https://doaj.org/article/b99c399b964c4f43a1cd36005d82d865Test

الإتاحة: https://doi.org/10.1111/1759-7714.15178Test
https://doaj.org/article/b99c399b964c4f43a1cd36005d82d865Test

المؤلفون: Karan, Sweta, Jung, Eunkyeong, Boone, Christine, Steinmetz, Nicole

المصدر: Cancer Immunology Immunotherapy, vol 73, iss 3

مصطلحات موضوعية: Checkpoint therapy, Cowpea mosaic virus, Intratumoral immunotherapy, Lag-3, Humans, Animals, Mice, Comovirus, Combined Modality Therapy, Immunotherapy, Disease Models, Animal, Melanoma

وصف الملف: application/pdf

العلاقة: qt7ph0k5sg; https://escholarship.org/uc/item/7ph0k5sgTest

الإتاحة: https://escholarship.org/uc/item/7ph0k5sgTest

المؤلفون: Bradley Garman, Can Jiang, Sherif Daouti, Sanah Kumar, Priyanka Mehta, Miye K. Jacques, Laurence Menard, Nataly Manjarrez-Orduno, Sonia Dolfi, Piali Mukherjee, Sharmila Chamling Rai, Ana Lako, Jennifer D. Koenitzer, Justin M. David

مصطلحات موضوعية: Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, Immunophenotyping, Immunotherapy, TIL, LAG-3, PD-1, CD8 memory T cell, MHC-II, galectin-3

العلاقة: https://figshare.com/articles/presentation/Presentation_1_Comprehensive_immunophenotyping_of_solid_tumor-infiltrating_immune_cells_reveals_the_expression_characteristics_of_LAG-3_and_its_ligands_pptx/24160152Test

الإتاحة: https://doi.org/10.3389/fimmu.2023.1151748.s001Test
https://figshare.com/articles/presentation/Presentation_1_Comprehensive_immunophenotyping_of_solid_tumor-infiltrating_immune_cells_reveals_the_expression_characteristics_of_LAG-3_and_its_ligands_pptx/24160152Test

المؤلفون: Gaona Neira, Geidi Catherinne, Salazar Prieto, Shanon Daniela, Rondón Lagos, Sandra Milena

المصدر: Ciencia En Desarrollo; Vol. 14 No. 2 (2023): Vol 14, Núm.2 (2023): Julio-Diciembre; 13-29 ; Ciencia en Desarrollo; Vol. 14 Núm. 2 (2023): Vol 14, Núm.2 (2023): Julio-Diciembre; 13-29 ; 2462-7658 ; 0121-7488

مصطلحات موضوعية: Anticuerpos monoclonales, Terapia antitumoral combinada, punto de control inmunitario, LAG-3, TIGIT, células T, Monoclonal antibodies, T cells, immune checkpoint, combined antitumor therapy

وصف الملف: application/pdf

العلاقة: https://revistas.uptc.edu.co/index.php/ciencia_en_desarrollo/article/view/15041/13669Test; https://revistas.uptc.edu.co/index.php/ciencia_en_desarrollo/article/view/15041Test

الإتاحة: https://doi.org/10.19053/01217488.v14.n2.2023.15041Test
https://revistas.uptc.edu.co/index.php/ciencia_en_desarrollo/article/view/15041Test